Wednesday - November 12, 2025

Hereditary Angioedema Market Forecast 2034 – Competitive Landscape, Clinical Trials, Market Size, Drug Analysis, Prevalence, Companies by DelveInsight

Hereditary Angioedema Market Hereditary Angioedema Companies are Takeda, CSL Behring, Intellia Therapeutics, Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, BioMarin Pharmaceutical, Pharvaris Netherlands B.V, Shire, and others Hereditary Angioedema Market Summary The Hereditary Angioedema market, valued at approximately USD 3 billion … Continue reading

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Set for Robust Growth Driven by Promising Pipeline Therapies and Advancements in Gene Editing Technologies | DelveInsight

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Key Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Companies, including Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Intellia Therapeutics, and Eidos Therapeutics. DelveInsight’s latest report, “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Insights, Epidemiology, and Market Forecast – 2032,” provides an in-depth … Continue reading

Systemic Lupus Erythematosus Market Poised for Transformative Growth Amid Roche’s Positive Phase III Results for Gazyva/Gazyvaro | DelveInsight

Systemic Lupus Erythematosus Market The leading Systemic Lupus Erythematosus Companies developing therapies include – Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, and others. DelveInsight’s “Systemic Lupus Erythematosus (SLE) Market Insights, Epidemiology, and Market … Continue reading

Acute Coronary Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight

Acute Coronary Syndrome Competitive Landscape Acute Coronary Syndrome companies include Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others. (Albany, USA) DelveInsight’s “Acute Coronary Syndrome – Pipeline Insight, 2025” highlights over 5+ active clinical assets targeting diverse mechanisms in … Continue reading